Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 61

Sort by

Sort Order Select

Journal Articles

Restoring p53 wild-type conformation in TP53 -Y220C–mutant acute myeloid leukemia

Bing Z. Carter, Po Yee Mak, Edward Ayoub, Xiaogang Wu, Baozhen Ke, Yuki Nishida, Andrew Futreal, Lauren B. Ostermann, Andrea D. Bedoy, Steffen Boettcher, Courtney D. DiNardo, Anna Puzio-Kuter, Masha V. Poyurovsky, Arnold Levine, Michael Andreeff

Blood (2025) 146 (21): 2574–2588.

https://doi.org/10.1182/blood.2025028935

Published: 2025

Includes: Supplemental data

Journal Articles

Protein degradation of MYC/GSPT1 combined with menin inhibition overcomes resistance to menin inhibition in KMT2A-rearranged Acute Myeloid Leukemia

Shayaun Khazaei, Shreya Nair, Lauren Ostermann, Hideaki Mizuno, Po Yee Mak, Bing Carter, Steffen Boettcher, Liandong Ma, Miriam Garcia, Branko Cuglievan, Alexandra McLean Stevens, Michael Andreeff, Yuki Nishida

Blood (2025) 146 (Supplement 1): 1510.

https://doi.org/10.1182/blood-2025-1510

Published: 2025

Journal Articles

Co-targeting menin and RAS in KMT2A-r/NPM1c AML with activated RTK//RAS/MAPK signaling

Bing Carter, Po Yee Mak, Vakul Mohanty, Xiaogang Wu, Khin The Nu Aye, Ken Chen, Branko Cuglievan, Michael Andreeff

Blood (2025) 146 (Supplement 1): 5060.

https://doi.org/10.1182/blood-2025-5060

Published: 2025

Journal Articles

Unidirectional synergy between ferroptosis and apoptosis reveals a novel therapeutic strategy for refractory AML

Blood (2025) 146 (Supplement 1): 5050.

https://doi.org/10.1182/blood-2025-5050

Published: 2025

Journal Articles

iPSC-derived mesenchymal stromal cells (iMSC) provide superior support for hematopoietic reconstitution compared to BM-MSCs

Olayinka Okeleji, Sandeep Singh, Andrea Bedoy, Lauren Ostermann, Kyle M. Garland, Po Yee Mak, Christopher Pacheco, Edward Ayoub, Ivo Veletic, Matthew Angel, Sanjeev Luther, Christopher Rohde, Michael Andreeff

Blood (2025) 146 (Supplement 1): 4957.

https://doi.org/10.1182/blood-2025-4957

Published: 2025

Journal Articles

Gene-modified iPSC-derived MSCs convert immunosuppressive tumor microenvironments (TMEs) into distinct Pro-inflammatory tmes

Muharrem Muftuoglu, Sandeep Singh, Andrea Bedoy, Li Li, Mahesh Basyal, Nath Dipmoy, Lauren Ostermann, Ivo Veletic, Christopher Pacheco, Po Yee Mak, Edward Ayoub, Taeyun Kim, Kyle Garland, Robert Pierce, Mathew Angel, Sanjeev Luther, Christopher Rohde, Michael Andreeff

Blood (2025) 146 (Supplement 1): 263.

https://doi.org/10.1182/blood-2025-263

Published: 2025

Journal Articles

CSF1R-CSF1 axis blockade with axatilimab effectively targets leukemia stem cells and monocytes in AML resistant to BH3 mimetics

Bing Carter, Po Yee Mak, Lauren Ostermann, Peter Ordentlich, Michael Andreeff

Blood (2025) 146 (Supplement 1): 3276.

https://doi.org/10.1182/blood-2025-3276

Published: 2025

Journal Articles

Cardio-safe degrader CT-03p degrades MCL-1 and overcomes venetoclax resistance in AML.

Po Yee Mak, Abhishek Maiti, Tomasz Tomczyk, Sylvian Cottens, Michal Walczak, Michael Andreeff, Bing Carter

Blood (2025) 146 (Supplement 1): 3266.

https://doi.org/10.1182/blood-2025-3266

Published: 2025

Journal Articles

Targeting Co-Regulatory Feedback Loop of MYC and GSPT1 By MYC/GSPT1 Dual Degradation Is Synthetic Lethal in Combination with Ven/Aza in TP53 Mutant Acute Myeloid Leukemia Stem and Progenitor Cells

Yuki Nishida, Hideaki Mizuno, Edward Ayoub, Eiji Sugihara, Lauren B. Ostermann, Shayaun Khazaei, Darah Scruggs, Po Yee Mak, Baozhen Ke, Bing Z. Carter, Abhishek Maiti, Liandong Ma, Michael Andreeff

Blood (2024) 144 (Supplement 1): 2755.

https://doi.org/10.1182/blood-2024-207812

Published: 2024

Journal Articles

Reactivation of p53 in TP53 -Y220C Mutant AML: Mechanism of Action and Mechanism-Based Drug Combinations

Bing Z. Carter, Po Yee Mak, Baozhen Ke, Xiaogang Wu, Steffen Boettcher, Lauren B. Ostermann, Andrea Bedoy, Georgina Gener-Ricos, Jayastu Senapati, Courtney D. DiNardo, Anna Puzio-Kuter, Arnold Levine, Michael Andreeff

Blood (2024) 144 (Supplement 1): 4155.

https://doi.org/10.1182/blood-2024-208403

Published: 2024

Journal Articles

Selective Targeting of TP53-Y220C Mutant AML By PC14586 Results in TP53 Wild-Type Conformation and Synergistical Apoptosis Induction By Concomitant Inhibition of Xpo-1, MDM2, or Bcl-2

Bing Z. Carter, Po Yee Mak, Baozhen Ke, Yuki Nishida, Steffen Boettcher, Andrea Bedoy, Lauren B. Ostermann, Courtney D. DiNardo, Anna Puzio-Kuter, Arnold Levine, Michael Andreeff

Blood (2023) 142 (Supplement 1): 2261.

https://doi.org/10.1182/blood-2023-181186

Published: 2023

Journal Articles

Stem-Cell Enriched Cellular Hierarchy of TP53 Mutant Acute Myeloid Leukemia Is Vulnerable to Targeted Protein Degradation of c-MYC

Blood (2023) 142 (Supplement 1): 583.

https://doi.org/10.1182/blood-2023-174938

Published: 2023

Journal Articles

Novel Hypomethylating Agent Ntx-301 Exhibits Anti-Leukemia Activity in Venetoclax-Resistant and TP53-Mutant AML

Bing Z. Carter, Po Yee Mak, Baozhen Ke, Andrea Bedoy, Steffen Boettcher, Lauren B. Ostermann, Elizabeth J. Shpall, Michael Andreeff

Blood (2023) 142 (Supplement 1): 4158.

https://doi.org/10.1182/blood-2023-180051

Published: 2023

Journal Articles

Calibrated Release IL15 Bivalent CD33 and/or FLT3 and NOT Emcn Logic Gated Gene Circuit CAR-NK Cell Therapy (SENTI-202) in Venetoclax Resistant Patient Derived Xenograft Acute Myeloid Leukemia Models

Muharrem Muftuoglu, Mahesh Basyal, Li Li, Jiangxing Lv, Lauren B. Ostermann, Ran Zhao, Baozhen Ke, Hiroki Akiyama, Po Yee Mak, Bing Z. Carter, Han Deng, Yongshuai Li, Brian S. Garrison, Kanya L. Rajangam, Michael Andreeff

Blood (2023) 142 (Supplement 1): 4831.

https://doi.org/10.1182/blood-2023-191127

Published: 2023

Journal Articles

Mitophagy As a Novel Cell-Protective Mechanism Against Mitochondrial Ferroptosis in Acute Myeloid Leukemia

Hiroki Akiyama, Matthew Tcheng, Priyanka Sharma, Ran Zhao, Lauren B. Ostermann, Samar Yazdani, Arman Moayed, Zdzislaw Szulc, Natalia Oleinik, Po Yee Mak, Vivian Ruvolo, Bing Z. Carter, Besim Ogretmen, Gautam Borthakur, Aaron D. Schimmer, Michael Andreeff, Jo Ishizawa

Blood (2023) 142 (Supplement 1): 2804.

https://doi.org/10.1182/blood-2023-181410

Published: 2023

Journal Articles

Epichaperome inhibition targets TP53- mutant AML and AML stem/progenitor cells

Blood (2023) 142 (12): 1056–1070.

https://doi.org/10.1182/blood.2022019047

Published: 2023

Includes: Supplemental data

Journal Articles

Inhibition of Menin, BCL-2, and FLT3 Combined with a Hypomethylating Agent Cures NPM1/FLT3 -ITD/-TKD Mutant AML in a PDX Model

Bing Z Carter, Po Yee Mak, Wenjing Tao, Lauren B Ostermann, Duncan Mak, Boazhen Ke, Peter Ordentlich, Gerard M. McGeehan, Michael Andreeff

Blood (2022) 140 (Supplement 1): 3063–3064.

https://doi.org/10.1182/blood-2022-158570

Published: 2022

Journal Articles

Mitochondrial Regulation of Ferroptosis in Acute Myeloid Leukemia

Hiroki Akiyama, Ran Zhao, Yuki Nishida, Natalia Baran, Ziyi Li, Lauren B Ostermann, Po Yee Mak, Edward Ayoub, Sujan Piya, Bing Z Carter, Michael Andreeff, Jo Ishizawa

Blood (2022) 140 (Supplement 1): 8785–8786.

https://doi.org/10.1182/blood-2022-162354

Published: 2022

Journal Articles

Epichaperome Inhibition Targets Kinase and TP53 Mutant Therapy Resistant AML

Bing Z Carter, Po Yee Mak, Wenjing Tao, Lauren B Ostermann, Yuki Nishida, Naveen Pemmaraju, Steffen Boettcher, Elizabeth J Shpall, Gabriela Chiosis, Georgios Karras, Barbara Wallner, Robert A Morgan, Michael Andreeff

Blood (2022) 140 (Supplement 1): 5930–5931.

https://doi.org/10.1182/blood-2022-158547

Published: 2022

Journal Articles

C-MYC Targeting By Degradation: Novel Dual c-Myc/GSPT1 Degrader GT19715 Induces TP53 -Independent Cell Death in Acute Myeloid Leukemia and Lymphomas

Yuki Nishida, Darah A Scruggs, Edward Ayoub, Tallie Patsilevas, Vivian Ruvolo, Po Yee Mak, Bing Z Carter, Steffen Boettcher, Abhishek Maiti, Qianxiang Zhou, Zhaohui Yang, Honghua Yan, Liandong Ma, Michael Andreeff

Blood (2022) 140 (Supplement 1): 483–484.

https://doi.org/10.1182/blood-2022-164968

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Restoring p53 wild-type conformation in TP53 -Y220C–mutant acute myeloid leukemia

Protein degradation of MYC/GSPT1 combined with menin inhibition overcomes resistance to menin inhibition in KMT2A-rearranged Acute Myeloid Leukemia

Co-targeting menin and RAS in KMT2A-r/NPM1c AML with activated RTK//RAS/MAPK signaling

Unidirectional synergy between ferroptosis and apoptosis reveals a novel therapeutic strategy for refractory AML

iPSC-derived mesenchymal stromal cells (iMSC) provide superior support for hematopoietic reconstitution compared to BM-MSCs

Gene-modified iPSC-derived MSCs convert immunosuppressive tumor microenvironments (TMEs) into distinct Pro-inflammatory tmes

CSF1R-CSF1 axis blockade with axatilimab effectively targets leukemia stem cells and monocytes in AML resistant to BH3 mimetics

Cardio-safe degrader CT-03p degrades MCL-1 and overcomes venetoclax resistance in AML.

Targeting Co-Regulatory Feedback Loop of MYC and GSPT1 By MYC/GSPT1 Dual Degradation Is Synthetic Lethal in Combination with Ven/Aza in TP53 Mutant Acute Myeloid Leukemia Stem and Progenitor Cells

Reactivation of p53 in TP53 -Y220C Mutant AML: Mechanism of Action and Mechanism-Based Drug Combinations

Selective Targeting of TP53-Y220C Mutant AML By PC14586 Results in TP53 Wild-Type Conformation and Synergistical Apoptosis Induction By Concomitant Inhibition of Xpo-1, MDM2, or Bcl-2

Stem-Cell Enriched Cellular Hierarchy of TP53 Mutant Acute Myeloid Leukemia Is Vulnerable to Targeted Protein Degradation of c-MYC

Novel Hypomethylating Agent Ntx-301 Exhibits Anti-Leukemia Activity in Venetoclax-Resistant and TP53-Mutant AML

Calibrated Release IL15 Bivalent CD33 and/or FLT3 and NOT Emcn Logic Gated Gene Circuit CAR-NK Cell Therapy (SENTI-202) in Venetoclax Resistant Patient Derived Xenograft Acute Myeloid Leukemia Models

Mitophagy As a Novel Cell-Protective Mechanism Against Mitochondrial Ferroptosis in Acute Myeloid Leukemia

Epichaperome inhibition targets TP53- mutant AML and AML stem/progenitor cells

Inhibition of Menin, BCL-2, and FLT3 Combined with a Hypomethylating Agent Cures NPM1/FLT3 -ITD/-TKD Mutant AML in a PDX Model

Mitochondrial Regulation of Ferroptosis in Acute Myeloid Leukemia

Epichaperome Inhibition Targets Kinase and TP53 Mutant Therapy Resistant AML

C-MYC Targeting By Degradation: Novel Dual c-Myc/GSPT1 Degrader GT19715 Induces TP53 -Independent Cell Death in Acute Myeloid Leukemia and Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only